Chuanshi Bio Completes Series B+ Financing Led by Shenzhen Capital Group with Continued Support from Existing Investors
VCBeat (WeChat ID: vcbeat) recently learned that Shenzhen Chuanshi Biomedical Co., Ltd. (hereinafter referred to as “Chuanshi Bio”) has announced the completion of its Series B+ financing round,The lead investor is Shenzhen Capital Group Co., Ltd. (SCGC), a top-tier Chinese investment institution, while existing shareholders of Chuanshi Biologics—Orient Fortune, Tsinghua Lihua, and CAS Star—continued to increase their stakes.The completion of this round of financing marks the active investment by capital in the IVD thrombosis and hemostasis sector, as well as the recognition of Chuanshi Bio’s development potential in this field.
ChuanShi Bio, established in 2017, is a Chinese brand enterprise driven by innovation, with deep expertise in the field of thrombosis and hemostasis. Notably, ChuanShi Bio pioneered the “opto-magnetic integrated” methodology, breaking away from the traditional paradigm of independent development and follow-on strategies in coagulation analysis technology, thereby ushering coagulation testing into an era of methodological integration.
In 2020, as an innovative medical device provider, Transmed Biotech was listed among the Top 40 Unicorn Enterprises in the Shenzhen Special Economic Zone’s 40th Anniversary rankings.
Chuan Shi Bio’s strategic entry into the thrombosis and hemostasis sector was driven by the opportunity for rapid growth in this niche, which is characterized by import monopolies and high market entry barriers.Dr. Zhang Huali, Founder and CEO of Chuanshi Biologicsstated, “Since Transcenta Holding was founded in 2017, our team has worked day and night for four years to develop the Yanxing series of products with professionalism. The performance of these products is on par with international standards, and Transcenta Holding also possesses unique advantages in product innovation and specific projects.”
In terms of marketing operations, Chuanshi Bio has established a sales network covering 31 provinces and municipalities across China, with a marketing team exceeding 60 members. Both its products and services have received consistent acclaim from clients during widespread adoption.
“Looking at the current landscape, thrombosis and hemostasis represent one of the few untapped ‘high-potential markets’ in the traditional IVD sector that have not yet seen a consolidated competitive structure. The next three to five years present a critical growth opportunity for Chuanshi Bio. We will remain committed to our philosophy of innovation-led development, focusing on creating product value. By upholding the principle of win-win collaboration, we will work closely with partners across the upstream and downstream value chain to seize industry opportunities, build a leading Chinese brand in thrombosis and hemostasis, and reshape the global competitive landscape in this field,” emphasized Dr. Zhang Huali.
As the lead investor in this financing round, Shenzhen Capital Group (SCGC) is a top-tier investment institution in China. Established in 1999 with capital contributed by the Shenzhen Municipal Government and guided social capital, it currently has a registered capital of RMB 10 billion and manages total assets of approximately RMB 421.3 billion. From 2016 to 2020, SCGC ranked first among domestic venture capital firms on Zero2IPO’s Annual Ranking of China’s Venture Capital Institutions for five consecutive years.
Dr. Zhou Yi, General Manager of SCGC Health FundAcknowledging the situation, they stated, “In the face of a coagulation testing market worth nearly RMB 10 billion that has long been monopolized by foreign manufacturers, Chuanshi Biology has independently developed and launched a fully automated dual-methodology coagulation testing system, adding a high-performance, high-quality domestic alternative to the market. In addition to continuously driving technological advancements in its products, Chuanshi Biology is actively expanding its portfolio and increasing investment in specialized coagulation assays. We anticipate that this financing round will accelerate team building and product R&D, thereby providing new tools for clinical laboratory departments in hospitals across China.”
The Series A investors of Chuanshi Bio areChen Huawei, Partner at Oriental Fortune CapitalHe also acknowledged, “Chuan Shi Bio boasts strong scientific research and innovation capabilities. Its independently developed ‘Yanxing’ series of coagulation analysis products innovatively integrates two classic technical approaches to coagulation testing—optical and magnetic bead methods—for the first time. With independent intellectual property rights, these products have received widespread acclaim from the industry since their launch. We highly appreciate the team’s efficient R&D capabilities and innovative thinking, and we look forward to seeing more blockbuster products brought to market in the future, delivering better innovative medical solutions that benefit patients.”
Angel Round InvestorFu Ying, Tsinghua Leaguer“The angel investors expressed: ‘We are delighted with the progress ChuanShi Bio has achieved to date. Remarkably, from its inception, the company established a comprehensive and well-coordinated team whose founding members possess deep insights into the IVD industry and clinical needs. At the outset, they strategically focused on the rapidly growing niche of thrombosis and hemostasis diagnostics, successfully building a portfolio of innovative products across multiple tiers. This positions the company to potentially achieve breakthrough import substitution with domestically developed solutions. We look forward to ChuanShi Bio’s rapid emergence as a leader in innovative R&D within the IVD sector.’”
Angel InvestorYu Xiang, CAS Star“He stated, ‘The diagnosis and treatment of cardiovascular diseases are key areas of focus for Sinostar’s investment strategy, and coagulation function testing plays a significant role in the diagnosis and management of these conditions. As the angel-round investor in Chuanshi Biology, Sinostar has consistently valued the company’s sustained product innovation capabilities and its strong team. The niche field of thrombosis and hemostasis offers substantial potential for import substitution, with the market landscape for domestic brands far from established. Chuanshi Biology possesses both the potential and the timely opportunity to emerge as a leading enterprise in this specialized sector.’”
Shenzhen Capital Group Co., Ltd. is committed to its mission of discovering and empowering great enterprises, striving to be a discoverer and cultivator of innovative value. Since its establishment in 1999, SCGC has managed total assets exceeding RMB 400 billion, invested in more than 1,000 innovative high-tech companies, of which 192 have gone public. Its portfolio spans industries such as information technology, internet, biotechnology/health, new energy/energy conservation and environmental protection, new materials, intelligent manufacturing, and consumer goods/modern services, covering the entire lifecycle of enterprises. It also extends to sectors including high-end equipment manufacturing and consumer goods/modern services, supporting companies throughout their full lifecycle.
Shenzhen Leaguer Venture Capital Co., Ltd. is a wholly-owned subsidiary of Leaguer Group. Its venture capital business, launched in 1999, serves as a key pillar of the Group’s technology services portfolio. The company is responsible for investing in and incubating the Group’s technology enterprises, working in close synergy with its applied R&D, talent training, and innovation base services. Distinguished by its focus on the commercialization of scientific and technological achievements, it is one of China’s earliest venture capital and incubation institutions dedicated to investing in high-tech enterprises. It has now established a full-chain investment service model, spanning from the investment and incubation of early-stage hard-tech projects to ongoing investment support for its portfolio companies.
After more than 20 years of development, Leaguer Group has cumulatively incubated and served over 2,500 enterprises, nurtured 30 listed companies, more than 50 companies listed on the National Equities Exchange and Quotations (NEEQ), over 300 national high-tech enterprises, and numerous star technology projects, achieving an average internal rate of return exceeding 30%.
Zhongke Star is China’s first professional platform dedicated to venture capital investment and incubation in hard technology. As the originator of the “hard technology” concept and a pioneer in hard technology investment, Zhongke Star is committed to building an integrated hard-tech entrepreneurship ecosystem that combines “research institutions + angel investment + entrepreneurial platforms + incubation services,” providing tech entrepreneurs with professional, in-depth, and comprehensive solutions for investment, incubation, and financing. Meanwhile, it explores science popularization and scientific education, actively assumes social responsibility, facilitates the industrialization of scientific and technological achievements, and promotes the deep integration of science and society. The company currently operates dual headquarters in Xi’an and Beijing.
Shenzhen Oriental Fortune Capital Investment Management Co., Ltd. (hereinafter referred to as "OFC" or "Oriental Fortune Capital") is a professional venture capital management firm founded by several industry experts with extensive experience, proven track records, outstanding investment performance, and significant influence in China’s venture capital sector. Since its establishment, the company has managed funds totaling nearly RMB 25 billion, with 52 funds currently under management. It has invested in over 480 projects, of which 125 have achieved exit through initial public offerings (IPOs), mergers and acquisitions (M&A), and other means. OFC is committed to investing in target companies with high growth potential and IPO prospects, actively providing value-added services to portfolio companies to enhance their profitability, and striving to help them maximize enterprise value through IPOs and other channels, thereby delivering satisfactory capital appreciation returns to investors.